Traumatic Brain Injuries Treatment Market Research Report Information By Treatment (Immediate Emergency Care, Medications {Diuretics, Anti-Seizure Drugs, Coma-Inducing Drugs, Anti-Anxiety Agents, Anti-Depressant, Anti-Psychotics, Analgesic, Anti-Convulsants, Anti-Coagulants}, and Surgery {Removing Clotted Blood, Repairing Skull Fracture, Bleeding in the Brain, Opening a Window in the Skull, and Rehabilitation}), By End-User (Hospitals, Neurologist, Independent Pharmacies, Rehabilitative Center Treatment, and Others) And By Region (North Ame

Global Traumatic Brain Injuries Treatment Market Overview

The traumatic brain injuries treatment market size was valued at USD 1.84 Billion in 2023. The traumatic brain injuries treatment industry is projected to grow from USD 1.99 Billion in 2024 to USD 3.54 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.42% during the forecast period (2024 - 2032). Growing innovations and advancements in technologies, extensive research and development activities, and a high volume of clinical trials being conducted to develop traumatic brain injuries are the key market drivers enhancing the market growth.

Source Secondary Research, MRFR Database, Primary Research and Analyst Review

Royal Philips, a global leader in health technology, and Synthetic MR, a company that specializes in magnetic resonance imaging (MRI) software solutions, announced the launch of Smart Quant Neuro 3D [1] in February 2024. This technology represents a significant advancement in the provision of objective decision support for the diagnosis and therapy assessment of brain disorders such as multiple sclerosis (MS), traumatic brain injury (TBI), and dementia. At Philips, we are collaborating with our customers to enhance productivity and access to more sustainable healthcare, as healthcare providers endeavor to provide high-quality care to patients. The Smart Quant Neuro 3D system integrates Philips' AI-based SmartSpeed image-reconstruction technology, Philips 3D SyntAc clinical application, and Synthetic MR's SyMRI NEURO 3D [2] quantitative tissue assessment software. Ultimately, patients are benefited by the combined offering, which provides healthcare providers with potent tools to increase diagnostic confidence. Philips is the sole company presently capable of providing SyMRI NEURO 3D capability on MR scanners as a result of its exclusive agreement with SyntheticMR.

Neuroshield CT TBI, an AI-based neurotrauma screening and quantification instrument, was introduced by In-Med AI in February 2024. NeuroShield CT, which is based on extensive imaging data and rigorous research, will assist neuro-critical teams in the identification and quantification of pathologies associated with Traumatic Brain Injury (TBI) cases. NeuroShield CT ensures accurate results in an expeditious manner by automating manual image processing through the use of AI. Radiologists, neurologists, and neurosurgeons are equipped with precise data through this cutting-edge technology, which enables them to make informed decisions quickly and efficiently regarding workflow prioritization, acute triage management, and the development of effective treatment plans for neurotrauma. TBI is frequently referred to as a "silent epidemic" and is the primary cause of hospitalization, disability, and post-injury mortality worldwide. Neuroshield CT functions as a decision support tool, promptly notifying neurologists of the presence of critical pathologies and providing quantifiable insights. NeuroShield CT offers critical information that equips neurologists with the knowledge required to enhance patient outcomes and implement targeted interventions.

Traumatic Brain Injuries Treatment Market Trends

• Growing traumatic brain injuries is driving the market growth

Market CAGR for traumatic brain injury treatment is driven by rising sports injuries, falls, gunshot wounds, domestic violence, and road traffic accidents. As per the CDC, traumatic brain injuries are responsible for 2.8 million accidents and emergency department visits annually in the US. Furthermore, as per Stanford Children's Health, around 3.5 million sports-related wounds are registered yearly among children in the US, and about 21% of all are traumatic brain injuries. Thus, increasing cases of traumatic brain injuries due to sports injuries, road accidents, and assaults are anticipated to fuel the market. The COVID-19 pandemic had a short-term and moderate impact on the market by directly affecting demand & production, disrupting the supply chain, and growth of the financial burden on firms.

Rising demand for minimally invasive neuro procedures owing to less pain and chances of infection and speedy recovery is expected to boost the demand for TBIs assessment and management devices. An increasing number of enterprises and programs being undertaken by the governments of different regions about brain injuries are expected to fuel the market growth. For instance, as an initiative toward traumatic brain injuries treatment, the Brain Injury Association of America (BIAA) organizes a national public awareness campaign every March to emphasize the importance of acknowledging the impact of brain injuries.

Furthermore, the growing population and rising per capita incomes have changed consumer demand for highly sophisticated and technologically advanced products and equipment. The increase in health awareness campaigns and programs that motivate individuals to take adequate care of their fitness and be more conscious of the diseases that can be carried on by utilizing certain products is a significant factor that drives the traumatic brain injuries treatment market revenue.

In addition, the increasing incidence of TBIs due to road accidents and falls in developed and developing regions has driven the establishment of technologically advanced products in the market. For instance, BrainScope, a U.S.-based company, has been granted over USD 32 million from the US Department of Defense research contracts to develop its BrainScope One device. It is an EEG-based non-invasive technology that enables decision-making on the spot.

Traumatic Brain Injuries Treatment Market Segment Insights

Traumatic Brain Injuries Treatment Insights

The traumatic brain injuries treatment market segmentation, based on treatment, includes (immediate emergency care, medications {diuretics, anti-seizure drugs, coma-inducing drugs, anti-anxiety agents, anti-depressant, anti-psychotics, analgesics, anti-convulsants, anti-coagulants}, and surgery {removing clotted blood, opening a window in the skull, repairing skull fracture, bleeding in the brain, and rehabilitation}. The surgery segment dominated the market, accounting for 35% of market revenue (0.64 Billion). In developing economies, category growth is driven by the growing occurrence of brain injuries among people due to trauma or accidents. However, medications are the fastest-growing category over the forecast period as it provides early and effective treatment.

Traumatic Brain Injuries Treatment End-User Insights

The traumatic brain injuries treatment market segmentation, based on end-user, includes hospitals, neurologists, independent pharmacies, rehabilitative center treatment, and others. The hospitals category generated the most income. This is due to an expansion in the number of brain surgeries performed in hospitals and an increase in the prevalence of TBI patients across the globe. Hospitals are well-equipped with technologically advanced devices that professional neurologists use. However, a neurologist is the fastest-growing category as most brain surgeries can be performed by a neurologist, as these procedures turn out to be more advanced and less invasive.

Figure 1 Traumatic Brain Injuries Treatment Market, by End-User, 2023 & 2032 (USD Billion)

Source Secondary Research, MRFR Database, Primary Research, and Analyst Review

Traumatic Brain Injuries Treatment Regional Insights

By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American traumatic brain injuries treatment market will dominate over the forecast period, owing to the existence of well-established healthcare facilities in the region, growing government initiatives, awareness campaigns regarding brain injuries, and greater incidence of TBIs in this region. Further, the US traumatic brain injuries treatment market held the largest market share, and the Canada traumatic brain injuries treatment market was the fastest growing market in the North America region.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2 TRAUMATIC BRAIN INJURIES TREATMENT MARKET SHARE BY REGION 2023 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe traumatic brain injuries treatment market accounts for the second-largest market share due to the growing patient affordability, have together resulted in a significant number of interventional procedures in the region. Further, the German traumatic brain injuries treatment market held the largest market share, and the UK traumatic brain injuries treatment market was the fastest growing market in the European region.

The Asia-Pacific traumatic brain injuries treatment market is expected to grow at the fastest CAGR from 2024 to 2032. This is due to an expansion in the incidence of road accidents and violence. Moreover, China traumatic brain injuries treatment market held the largest market share, and the Indian traumatic brain injuries treatment market was the fastest-growing market in the Asia-Pacific region.

Traumatic Brain Injuries Treatment Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development to expand their product lines, which will help the traumatic brain injuries treatment market grow even more. Market participants are also undertaking numerous strategic activities to expand their footprint, with important market developments including new product establishments, mergers and acquisitions, higher investments, contractual agreements, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the traumatic brain injury treatment industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics manufacturers use in the  traumatic brain injury treatment industry to benefit clients and increase the market sector. In recent years, the traumatic brain injury treatment industry has offered some of the most significant advantages to medicine. Major players in the traumatic brain injuries treatment market, including Zimmer Biomet, Neuren Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Medicortex Finland Oy, AMARANTUS BIOSCIENCE HOLDINGS, INC., Stemedica Cell Technologies, Inc., and others, are attempting to increase market demand by investing in research and development operations.

Integra LifeSciences Holdings Corp is a medical technology firm that develops and manufactures engineered collagen-based product lines. The firm's portfolio comprises advanced wound care, surgical instruments, specialty metal implants, orthobiologic products, dermal regeneration products, tissue-engineered injury dressings, and nerve and tendon repair products. Its neurosurgery products such as ultrasonic surgery systems, systems for measuring several brain parameters, cranial stabilization and brain retraction systems, and others. Integra's products find application in neurosurgery, orthopedic extremity surgery, and reconstructive and general surgery. Integra serves outpatient surgery centers, hospitals, physicians, veterinarians and dental practices. The firm markets its solutions through direct market representatives and an extensive network of distributors ly. In September 2019, Integra Life Sciences completed the acquisition of Rebound Therapeutics, a manufacturer of disposable medical devices. With this acquisition, the company developed new products and a minimally invasive platform for neurosurgery.

Nihon Kohden Corp (Nihon Kohden) develops, manufactures and commercializes electronic medical equipment and other systems to support treatment in clinical areas of emergency response, testing, diagnosis, treatment, and rehabilitation. Its major products include patient monitors, electroencephalographs, evoked potential and electromyograph systems, electrocardiographs, defibrillators and hematology analyzers. These products find applications in health management, home medical care, nursing and basic medical research. The company operates through branch offices and direct sales personnel in Japan and subsidiaries and distributors across the globe. Nihon Kohden is headquartered in Tokyo, Japan. In June 2019, Nihon Kohden launched a wireless Electroencephalogram (EEG) headset in the US called VitalEEG to promptly assess brain activity in unconscious patients.

Key Companies in the Traumatic Brain Injuries Treatment market include

• Zimmer Biomet


• Neuren Pharmaceuticals Ltd.


• Oxygen Biotherapeutics Inc


• Teva Pharmaceutical Industries Ltd


• Ischemic


• Grace Laboratories LLC


• Medicortex


• Amarantus BioScience Holdings


• Aldagen


• NeuroScience Pharmaceuticals


• Targacept


• BioDirection, Inc.


• QuesGen Systems, Inc.


• BrainScope Company, Inc.


• Neural Analytics, Inc


• Oculogica


• BrainScope Company, Inc

Traumatic Brain Injuries Treatment Industry Developments

March 2023 Abbott has received US Food and Drug Administration clearance for the first commercially available laboratory traumatic brain injury (TBI) blood test, making it widely available to hospitals in the United States. The test, which runs on Abbott's Alinity® I laboratory instrument, will provide clinicians with an objective way to quickly assess individuals with mild TBIs, also known as concussions.

November 2021 BioDirection Company, a privately held medical device firm developing novel and rapid point-of-care products for the objective diagnosis and management of traumatic brain injury (TBI), launched its new product, namely, NanoDx System. It is a rapid point-of-care testing system that can precisely confirm concussion or TBI in less than 2 minutes.

Traumatic Brain Injuries Treatment Market Segmentation

Traumatic Brain Injuries Treatment Outlook

• Immediate Emergency Care


• 
  Medications
  
  
  
  • Diuretics
  
  
  • Anti-Seizure Drugs
  
  
  • Coma-Inducing Drugs
  
  
  • Anti-Anxiety Agents
  
  
  • Anti-Depressant
  
  
  • Anti-Psychotics
  
  
  • Analgesic
  
  
  • Anti-Convulsants
  
  
  • Anti-Coagulants
  
  
  
  


• 
  Surgery
  
  
  
  • Removing Clotted Blood
  
  
  • Repairing Skull Fracture
  
  
  • Bleeding in the Brain
  
  
  • Opening a Window in the Skull
  
  
  • Rehabilitation
  
  
  
  

Traumatic Brain Injuries Treatment End-User Outlook

• Hospitals


• Neurologist


• Independent Pharmacies


• Rehabilitative Center Treatment


• Others

Traumatic Brain Injuries Treatment Regional Outlook

• 
  North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• 
  Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• 
  Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• 
  Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America
  
  
  
  

Report Attribute/Metric	Details
Market Size 2023	USD 1.84 Billion
Market Size 2024	USD 1.99 Billion
Market Size 2032	USD 3.54 Billion
Compound Annual Growth Rate (CAGR)	7.42% (2024-2032)
Base Year	2023
Market Forecast Period	2024-2032
Historical Data	2018- 2022
Market Forecast Units	Value (USD Billion)
Report Coverage	Market Competitive Landscape, Growth Factors, Revenue Forecast, and Trends
Segments Covered	Treatment, End-User and Region
Geographies Covered	North America, Europe, Asia Pacific, and the Rest of the World
Countries Covered	The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
Key Companies Profiled	Zimmer Biomet, Neuren Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Medicortex Finland Oy, AMARANTUS BIOSCIENCE HOLDINGS, INC., Stemedica Cell Technologies, Inc., BANYAN BIOMARKERS, INC., BioDirection, QuesGen Systems, Inc., and Neural Analytics, Inc.
Key Market Opportunities	Numerous clinical trials are being conducted to develop traumatic brain injuries.
Key Market Dynamics	Extensive research and development activities